Status:
COMPLETED
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Lead Sponsor:
Karius, Inc.
Collaborating Sponsors:
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Invasive Fungal Disease
Fever and Neutropenia
Eligibility:
All Genders
Brief Summary
The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
Detailed Description
The Sponsor aims to describe the incidence of positivity for fungal specific pathogens on NGS analysis in a high-risk immunocompromised pediatric population. Secondarily, the Sponsor will correlate r...
Eligibility Criteria
Inclusion
- Prolonged FN (≥96 hours) despite broad-spectrum antibiotic therapy with anticipated delayed neutrophil recovery
- Any findings that trigger the primary team to consider new fungal infection in a given inpatient, such as abnormal imaging results, recrudescent fevers in the setting of neutropenia or characteristic skin rashes
Exclusion
- Those without concern for fungal infection or those currently being treated for a presumed or documented fungal infection will not be recruited for this study
Key Trial Info
Start Date :
May 17 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 28 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03262584
Start Date
May 17 2017
End Date
September 28 2018
Last Update
June 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611